

# Su-jun Zheng

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5443037/publications.pdf>

Version: 2024-02-01

71  
papers

784  
citations

567281  
15  
h-index

677142  
22  
g-index

73  
all docs

73  
docs citations

73  
times ranked

1322  
citing authors

#	ARTICLE	IF	CITATIONS
1	Vitamin D deficiency promotes nonalcoholic steatohepatitis through impaired enterohepatic circulation in animal model. American Journal of Physiology - Renal Physiology, 2014, 307, G883-G893.	3.4	50
2	M2-like macrophages in the fibrotic liver protect mice against lethal insults through conferring apoptosis resistance to hepatocytes. Scientific Reports, 2017, 7, 10518.	3.3	46
3	M2-like macrophages exert hepatoprotection in acute-on-chronic liver failure through inhibiting necroptosis-S100A9-necroinflammation axis. Cell Death and Disease, 2021, 12, 93.	6.3	40
4	Persistence of cirrhosis is maintained by intrahepatic regulatory T cells that inhibit fibrosis resolution by regulating the balance of tissue inhibitors of metalloproteinases and matrix metalloproteinases. Translational Research, 2016, 169, 67-79.e2.	5.0	28
5	Prognostic value of M30/M65 for outcome of hepatitis B virus-related acute-on-chronic liver failure. World Journal of Gastroenterology, 2014, 20, 2403.	3.3	25
6	Cationic Polystyrene Resolves Nonalcoholic Steatohepatitis, Obesity, and Metabolic Disorders by Promoting Eubiosis of Gut Microbiota and Decreasing Endotoxemia. Diabetes, 2017, 66, 2137-2143.	0.6	24
7	Cathepsin H-Mediated Degradation of HDAC4 for Matrix Metalloproteinase Expression in Hepatic Stellate Cells. American Journal of Pathology, 2017, 187, 781-797.	3.8	23
8	Serum sphingomyelin has potential to reflect hepatic injury in chronic hepatitis B virus infection. International Journal of Infectious Diseases, 2015, 33, 149-155.	3.3	21
9	Non-HFE mutations in haemochromatosis in China: combination of heterozygous mutations involving HJV signal peptide variants. Journal of Medical Genetics, 2018, 55, 650-660.	3.2	21
10	Hepatitis B Virus X Protein Stabilizes Cyclin D1 and Increases Cyclin D1 Nuclear Accumulation through ERK-Mediated Inactivation of GSK-3 $\beta$ . Cancer Prevention Research, 2015, 8, 455-463.	1.5	20
11	Peroxisome proliferator-activated receptor alpha acts as a mediator of endoplasmic reticulum stress-induced hepatocyte apoptosis in acute liver failure. DMM Disease Models and Mechanisms, 2016, 9, 799-809.	2.4	19
12	Plasma sphingolipids: Potential biomarkers for severe hepatic fibrosis in chronic hepatitis C. Molecular Medicine Reports, 2015, 12, 323-330.	2.4	18
13	Current treatment status and barriers for patients with chronic HCV infection in mainland China. Medicine (United States), 2017, 96, e7885.	1.0	18
14	HBeAg-positive patients with HBsAg $\leq 100$ IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. Journal of Gastroenterology, 2021, 56, 856-867.	5.1	18
15	Serum Sphingolipids Reflect the Severity of Chronic HBV Infection and Predict the Mortality of HBV-Acute-on-Chronic Liver Failure. PLoS ONE, 2014, 9, e104988.	2.5	18
16	Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study. Hepatology, 2022, 75, 1373-1385.	7.3	17
17	Selection of reference genes for RT-qPCR analysis in tumor tissues from male hepatocellular carcinoma patients with hepatitis B infection and cirrhosis. Cancer Biomarkers, 2013, 13, 345-349.	1.7	16
18	Glucosylceramide synthase regulates the proliferation and apoptosis of liver cells in vitro by Bcl-2/Bax pathway. Molecular Medicine Reports, 2017, 16, 7355-7360.	2.4	16

#	ARTICLE	IF	CITATIONS
19	Genetically Regulated Bilirubin and Risk of Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study. <i>Frontiers in Genetics</i> , 2018, 9, 662.	2.3	16
20	Complex <i>ATP7B</i> mutation patterns in Wilson disease and evaluation of a yeast model for functional analysis of variants. <i>Human Mutation</i> , 2019, 40, 552-565.	2.5	16
21	Plasma Sphingolipids as Potential Indicators of Hepatic Necroinflammation in Patients with Chronic Hepatitis C and Normal Alanine Aminotransferase Level. <i>PLoS ONE</i> , 2014, 9, e95095.	2.5	16
22	Inhibition of 5-Lipoxygenase Pathway Attenuates Acute Liver Failure by Inhibiting Macrophage Activation. <i>Journal of Immunology Research</i> , 2014, 2014, 1-9.	2.2	15
23	Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge. <i>Molecular Medicine Reports</i> , 2016, 13, 3835-3841.	2.4	15
24	Efficient inhibition of duck hepatitis B virus DNA by the CRISPR/Cas9 system. <i>Molecular Medicine Reports</i> , 2017, 16, 7199-7204.	2.4	15
25	Immune Regulation of Intrahepatic Regulatory T Cells in Fibrotic Livers of Mice. <i>Medical Science Monitor</i> , 2017, 23, 1009-1016.	1.1	15
26	Fibrosis progression in interferon treatment-naïve Chinese plasma donors with chronic hepatitis C for 20 years: a cohort study. <i>International Journal of Infectious Diseases</i> , 2014, 27, 49-53.	3.3	14
27	Stevens-Johnson syndrome and acute vanishing bile duct syndrome after the use of amoxicillin and naproxen in a child. <i>Journal of International Medical Research</i> , 2019, 47, 4537-4543.	1.0	14
28	Efficacy and Safety of All-oral, 12-week Ravidasvir Plus Ritonavir-boosted Danoprevir and Ribavirin in Treatment-naïve Noncirrhotic HCV Genotype 1 Patients: Results from a Phase 2/3 Clinical Trial in China. <i>Journal of Clinical and Translational Hepatology</i> , 2019, 7, 1-8.	1.4	12
29	Mutation analysis of the <i>ABCC2</i> gene in Chinese patients with Dubin-Johnson syndrome. <i>Experimental and Therapeutic Medicine</i> , 2018, 16, 4201-4206.	1.8	11
30	Pegylated Interferon Treatment for the Effective Clearance of Hepatitis B Surface Antigen in Inactive HBsAg Carriers: A Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 779347.	4.8	11
31	Exploring the Diagnostic Potential of Serum Golgi Protein 73 for Hepatic Necroinflammation and Fibrosis in Chronic HCV Infection with Different Stages of Liver Injuries. <i>Disease Markers</i> , 2019, 2019, 1-10.	1.3	10
32	Serum vitamin D <sub>3</sub> does not correlate with liver fibrosis in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 11152.	3.3	10
33	Cellular Mechanisms of Hepatoprotection Mediated by M2-Like Macrophages. <i>Medical Science Monitor</i> , 2018, 24, 2675-2682.	1.1	9
34	Upregulation of Serum Sphingosine (d18:1)-1-P Potentially Contributes to Distinguish HCC Including AFP-Negative HCC From Cirrhosis. <i>Frontiers in Oncology</i> , 2020, 10, 1759.	2.8	9
35	Coblopassvir and sofosbuvir for treatment of chronic hepatitis C virus infection in China: A single-arm, open-label, phase 3 trial. <i>Liver International</i> , 2020, 40, 2685-2693.	3.9	9
36	Autoantibody Response to Murine Double Minute 2 Protein in Immunodiagnosis of Hepatocellular Carcinoma. <i>Journal of Immunology Research</i> , 2014, 2014, 1-10.	2.2	8

#	ARTICLE	IF	CITATIONS
37	Combined Effects of UGT1A1 and SLCO1B1 Variants on Chinese Adult Mild Unconjugated Hyperbilirubinemia. <i>Frontiers in Genetics</i> , 2019, 10, 1073.	2.3	8
38	Comparison of the Effectiveness and Safety of d-Penicillamine and Zinc Salt Treatment for Symptomatic Wilson Disease: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2022, 13, 847436.	3.5	8
39	Efficacy of antepartum administration of hepatitis B immunoglobulin in preventing mother-to-child transmission of hepatitis B virus. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1059-1065.	2.0	7
40	Phenotypic switch of human and mouse macrophages and resultant effects on apoptosis resistance in hepatocytes. <i>Innate Immunity</i> , 2019, 25, 176-185.	2.4	7
41	A standardized assay for the quantitative detection of serum HBV RNA in chronic hepatitis B patients. <i>Emerging Microbes and Infections</i> , 2022, 11, 775-785.	6.5	7
42	Clinical and Immunological Factors Associated with Postpartum Hepatic Flares in Immune-Tolerant Pregnant Women with Hepatitis B Virus Infection Treated with Telbivudine. <i>Gut and Liver</i> , 2021, 15, 887-894.	2.9	6
43	Serum HBV RNA predicts HBeAg clearance and seroconversion in patients with chronic hepatitis B treated with nucleos(t)ide analogues. <i>Journal of Viral Hepatitis</i> , 2022, 29, 420-431.	2.0	6
44	Prevalence of Major Depression and Its Associations With Demographic and Clinical Characteristics and Quality of Life in Chinese Patients With HBV-related Liver Diseases. <i>Archives of Psychiatric Nursing</i> , 2017, 31, 287-290.	1.4	5
45	Clinical Features and T Cell Immune Characteristics of Postpartum Hepatitis Flare in Pregnant Women With HBeAg-Positive Chronic HBV Infection. <i>Frontiers in Immunology</i> , 2022, 13, 881321.	4.8	5
46	Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy. <i>International Journal of Medical Sciences</i> , 2015, 12, 416-422.	2.5	4
47	Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B. <i>Experimental and Therapeutic Medicine</i> , 2016, 11, 2293-2299.	1.8	4
48	Risk factors related to postpartum hepatic inflammation in pregnant women with chronic hepatitis B. <i>Journal of International Medical Research</i> , 2020, 48, 030006052096643.	1.0	4
49	A novel compound heterozygous mutation in ABCB4 gene in a pedigree with progressive familial intrahepatic cholestasis 3: a case report. <i>Annals of Translational Medicine</i> , 2021, 9, 426-426.	1.7	4
50	Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis. <i>BMC Gastroenterology</i> , 2021, 21, 490.	2.0	4
51	Coverage of different health insurance programs and medical costs associated with chronic hepatitis C infection in mainland China: a cross-sectional survey in 20 provinces. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 7.	1.7	3
52	Novel mutations found in the ATP7B gene in Chinese patients with Wilson's disease. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2019, 7, e649.	1.2	3
53	Seraprevir and sofosbuvir for treatment of chronic hepatitis C virus infection: A single-arm, open-label, phase 3 trial. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2375-2382.	2.8	3
54	Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China. <i>Annals of Translational Medicine</i> , 2021, 9, 1365-1365.	1.7	3

#	ARTICLE	IF	CITATIONS
55	Changes in Mitochondrial Toxicity in Peripheral Blood Mononuclear Cells During Four-Year Administration of Entecavir Monotherapy in Chinese Patients with Chronic Hepatitis B. Medical Science Monitor, 2015, 21, 2058-2063.	1.1	3
56	Stem Cells Treatment for Wilson Disease. Current Stem Cell Research and Therapy, 2022, 17, 712-719.	1.3	3
57	Serum Anti-14-3-3 Zeta Autoantibody as a Biomarker for Predicting Hepatocarcinogenesis. Frontiers in Oncology, 2021, 11, 733680.	2.8	3
58	Respiratory failure as the prominent manifestation of entecavir-associated mitochondrial myopathy: a case report. BMC Infectious Diseases, 2022, 22, 188.	2.9	3
59	Increased glyceraldehyde-3-phosphate dehydrogenase expression indicates higher survival rates in male patients with hepatitis B virus-associated hepatocellular carcinoma and cirrhosis. Experimental and Therapeutic Medicine, 2015, 9, 1597-1604.	1.8	2
60	Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy. Experimental and Therapeutic Medicine, 2016, 11, 117-123.	1.8	2
61	Prevalence and clinical correlates of insomnia symptoms and their association with quality of life in Chinese patients with HBV-related liver disease. PeerJ, 2021, 9, e10956.	2.0	2
62	UGT1A1-related Bilirubin Encephalopathy/Kernicterus in Adults. Journal of Clinical and Translational Hepatology, 2021, 000, 000-000.	1.4	2
63	The Psychometric Properties of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) in Patients with HBV-Related Liver Disease. Shanghai Archives of Psychiatry, 2017, 29, 15-20.	0.7	2
64	Efficacy and Safety of All-oral Emitasvir and Sofosbuvir in Patients with Genotype 1b HCV Infections without Cirrhosis. Journal of Clinical and Translational Hepatology, 2020, 8, 1-7.	1.4	2
65	Platelet count is closely associated with the severity of liver injury in patients with chronic hepatitis B virus infection: A cross-sectional study. Experimental and Therapeutic Medicine, 2020, 20, 243-250.	1.8	2
66	Direct-acting Antiviral-induced Transient Recovery of NK Cells in Early-stage Treatment of Chronic Hepatitis C Patients. Journal of Clinical and Translational Hepatology, 2022, 000, 000-000.	1.4	2
67	Changing Interdigestive Migrating Motor Complex in Rats under Acute Liver Injury. BioMed Research International, 2014, 2014, 1-7.	1.9	1
68	Identification of sphingolipids as novel noninvasive biomarkers of liver damage caused by chronic hepatitis B. FASEB Journal, 2013, 27, 815.1.	0.5	1
69	Letter to the Editor: Suggestions for Rational Management of Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 70, 1492-1493.	7.3	0
70	Cover Image, Volume 40, Issue 5. Human Mutation, 2019, 40, i-i.	2.5	0
71	A Novel Mutation of Transferrin Receptor 2 in a Chinese Pedigree With Type 3 Hemochromatosis: A Case Report. Frontiers in Genetics, 2022, 13, 836431.	2.3	0